Search

Displaying results 4311 - 4320 of 5449 in total
  1. Drug

    Zidesamtinib

    go.drugbank.com/drugs/DB21623
    ApprovedInvestigational

    [L63808,L63933] Zidesamtinib is selective for ROS1, retains activity in cells carrying the common resistance mutations, and showed antitumor activity in an intracranial model, positioning it for use after

  2. Drug

    CP-122721

    go.drugbank.com/drugs/DB05421
    Experimental

    CP-122721, neurokinin 1 (NK1) antagonist is developed by Pfizer to treat depression, emesis, and inflammatory diseases including asthma and irritable bowel syndrome.

  3. Drug

    Azvudine

    go.drugbank.com/drugs/DB16407
    Investigational

    Azvudine is under investigation in clinical trial NCT04668235 (Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (Sars-cov-2 Infected)).

  4. Drug

    ALS-08

    go.drugbank.com/drugs/DB05705
    Experimental

    It is being developed by Avicena Group, Inc.

  5. Drug

    Contulakin-G

    go.drugbank.com/drugs/DB05950
    Experimental

    It is the synthetic form of a natural peptide extracted from the venom of the Conus Geographus sea snail.

  6. Drug

    Otamixaban

    go.drugbank.com/drugs/DB06635
    Investigational

    It is currently being developed by the French pharmaceutical company Sanofi-Aventis as a treatment for acute coronary syndrome.

  7. Drug

    Arsanilic acid

    go.drugbank.com/drugs/DB03006
    ExperimentalVet approved

    It causes blindness and is ototoxic and nephrotoxic in animals. [PubChem]

  8. Drug

    Florzolotau F-18

    go.drugbank.com/drugs/DB16297
    Investigational

    PMPBB3 F-18 is under investigation in clinical trial NCT04305210 (Alzheimer's Disease: Clinical Investigation and Neuroimage Studies Including 18F-PM-PBB3 and 18f-florbetapir (AV-45) PET Examination).

  9. Drug

    Rocakinogene sifuplasmid

    go.drugbank.com/drugs/DB16316
    Investigational

    Rocakinogene sifuplasmid is under investigation in clinical trial NCT03491683 (INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-diagnosed Glioblastoma

  10. Drug

    ASP-8731

    go.drugbank.com/drugs/DB17696
    Investigational

    Developed by Mitobridge, it is being investigated for the treatment of sickle cell disease.[L46093]